The utility of the Health Plan Employer Data and Information Set (HEDIS) asthma measure to predict asthma-related outcomes

Berger, William; Legorreta, Antonio P.; Blaiss, Michael S.; Schneider, Eric C.; Luskin, Allan T.; Stempel, David A.; Suissa, Samy; Goodman, David C.; Stoloff, Stuart W.; Chapman, Jean A.; Sullivan, Sean D.; Vollmer, Bill; Weiss, Kevin B.

doi:10.1016/s1081-1206(10)61260-4

Cited by 45 publications

(32 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…That stated, these data sets are used by the National Committee for Quality Assurance to measure quality. 27 Claims data have no universally accepted measure of disease severity. The regression models are therefore used to adjust for baseline differences.…”

Section: Discussionmentioning

confidence: 99%

Asthma-related exacerbations, therapy switching, and therapy discontinuation: a comparison of 3 commonly used controller regimens

O’Connor

Rosenzweig

Stanford

et al. 2005

Annals of Allergy, Asthma & Immunology

Self Cite

View full text Add to dashboard Cite

Background: Asthma control is the goal of therapeutic interventions. In observational studies, the use of short-acting ␤-agonists (SABAs) is a surrogate for symptoms and emergency department or hospital events for exacerbations.Objective: To compare asthma exacerbations, medication switch, and use of SABAs among 3 treatment cohorts: fluticasone propionate and salmeterol as a single inhaler (FSC), fluticasone and salmeterol as separate inhalers (FP ϩ SAL), and fluticasone propionate alone (FP).Methods: Administrative claims data from approximately 10 million individuals from April 2000 to December 2002 were examined. Patients 15 years or older with claims for asthma, SABAs, and study medications were included in the study. Asthma-related medical and pharmacy claims were evaluated. Multivariate regression techniques were used to model the outcomes of interest, controlling for patient characteristics.Results: The odds of a hospitalization or emergency department event were significantly lower for the patients receiving FSC (n ϭ 1,013) compared with those receiving FP (n ϭ 1,130) (odds ratio, 0.75; 95% confidence interval, 0.61-0.93) and those receiving FP ϩ SAL (n ϭ 271) (odds ratio, 0.69; 95% confidence interval, 0.51-0.95). Patients receiving FSC also had a significantly lower risk of switch or discontinuation of index medication and lower rates of postindex SABA use.Conclusion: In this analysis, patients receiving FSC had lower rates of asthma-related symptoms and exacerbations as measured by SABA refills and hospitalization, respectively, when compared with patients receiving either FP or FP ϩ SAL. This observational examination of medical and pharmacy claims data adds to the clinical reports that demonstrate the increased effectiveness of FSC when compared with FP or FP ϩ SAL.Ann Allergy Asthma Immunol. 2005;95:535-540.

show abstract

Section: Discussionmentioning

confidence: 99%

Asthma-related exacerbations, therapy switching, and therapy discontinuation: a comparison of 3 commonly used controller regimens

O’Connor

Rosenzweig

Stanford

et al. 2005

Annals of Allergy, Asthma & Immunology

Self Cite

View full text Add to dashboard Cite

show abstract

“…First, patients had to meet the Health Plan Employer Data and Information Set (HEDIS) criteria for persistent asthma during the 12-month entry eligibility period after the first asthma diagnosis (n 5 28,390). [12][13][14] The HEDIS criteria for persistent asthma require patients to have (1) at least 1 inpatient hospitalization with asthma as a primary discharge diagnosis, (2) at least 1 emergency department (ED) visit with a primary asthma diagnosis, (3) at least 4 claims for asthma prescription medications dispensed, or (4) at least 4 outpatient visits with an asthma diagnosis and at least 2 claims for asthma prescription medications dispensed. Asthma prescription medications included quick-relief medications (short-acting inhaled b 2 -agonists [SABAs] and other relievers), controllers (inhaled corticosteroids [ICSs], combination ICS plus long-acting inhaled b 2 -agonist [LABA], and other controllers), biologic agents, and systemic corticosteroids.…”

Section: Abbreviations Usedmentioning

confidence: 99%

Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma

Ivanova

Bergman

Birnbaum

et al. 2012

Journal of Allergy and Clinical Immunology

265

168

View full text Add to dashboard Cite

“…One study in children demonstrated such a relationship, 17 but 3 studies in children and adults failed to show that improved performance on this measure is associated with improved asthma outcomes. [18][19][20] The lack of a relationship of the HEDIS asthma measure to improved outcomes has led to the search for an improved asthma quality-of-care measure based on administrative data that would be associated with improved outcomes. The medication ratio measure has been defined from computerized pharmacy data as the ratio of controllers to total asthma medications (controllers plus relievers) dispensed in a 12-month period.…”

Section: Quality Of Carementioning

confidence: 99%

Improving asthma outcomes in large populations

Schätz

Zeiger

2011

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

The utility of the Health Plan Employer Data and Information Set (HEDIS) asthma measure to predict asthma-related outcomes

Cited by 45 publications

References 30 publications

Asthma-related exacerbations, therapy switching, and therapy discontinuation: a comparison of 3 commonly used controller regimens

Asthma-related exacerbations, therapy switching, and therapy discontinuation: a comparison of 3 commonly used controller regimens

Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma

Improving asthma outcomes in large populations

Contact Info

Product

Resources

About